Arbutus Biopharma
ABUS
ABUS
71 hedge funds and large institutions have $158M invested in Arbutus Biopharma in 2018 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 18 increasing their positions, 11 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
42% more funds holding
Funds holding: 50 → 71 (+21)
6.94% more ownership
Funds ownership: 33.37% → 40.32% (+6.9%)
Holders
71
Holding in Top 10
1
Calls
$2.01M
Puts
$933K
Top Buyers
| 1 | +$12.4M | |
| 2 | +$8.52M | |
| 3 | +$3.54M | |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$2.16M |
| 5 |
Goldman Sachs
New York
|
+$1.8M |
Top Sellers
| 1 | -$2.68M | |
| 2 | -$1.75M | |
| 3 | -$1.45M | |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$1.28M |
| 5 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$951K |